| 臺大學術典藏 |
2022-02-14T05:27:16Z |
The Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Guidelines for Contrast-Enhanced Endoscopic Ultrasound
|
Kitano M.; Yamashita Y.; Kamata K.; Ang T.L.; Imazu H.; Ohno E.; Hirooka Y.; Fusaroli P.; Seo D.-W.; Napoléon B.; Teoh A.Y.B.; Kim T.H.; Dietrich C.F.; HSIU-PO WANG; Kudo M.; Working group for the International Consensus Guidelines for Contrast-Enhanced Harmonic Endoscopic Ultrasound |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata M.; Lesmana L.A.; Tateishi R.; Chen P.-J.; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Liver cancer working group report
|
Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Needs for hepatocellular carcinoma control policy in the Asia-Pacific region
|
Bridges J.F.P.; Joy S..; Gallego G.; Kudo M.; Ye S.-L.; Han K.-H.; ANN-LII CHENG; Blauvelt B. |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia
|
Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-09-01T01:53:42Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
ANN-LII CHENG; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
|
ANN-LII CHENG; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
|
ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; ANN-LII CHENG; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial
|
Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
|
Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
|
Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG |
